V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10451435 | 10042039 | 1.62 | 68.5 | Curative (C) | 2019-07-31 | 2019-08-12 | null | 02 | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100533230 |
| 10451466 | 10042040 | 1.73 | 61 | Curative (C) | 2019-06-15 | 2019-06-17 | Doxorubicin + Olaratumab | 02 | N | STAMPEDE TRIAL | 101657859 |
| 10451495 | 10042041 | 1.68 | 80 | Palliative (P) | 2018-04-27 | 2018-04-30 | RCEOP | 02 | N | OBINUTUZUMAB + VENETOCLAX | 100123789 |
| 10451525 | 10042042 | 1.71 | 72 | Curative (C) | null | 2020-10-14 | FLUOROURACIL + OXALIPLATIN | null | N | LENALIDOMIDE + RITUXIMAB | 101813115 |
| 10451540 | 10042043 | 1.7 | 76 | Adjuvant (A) | 2017-01-26 | 2017-01-29 | Fulvestrant + Palbociclib | 02 | N | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + METHOTREXATE + RITUXIMAB + VINCRISTINE | 101579165 |
| 10451548 | 10042044 | 1.68 | 75.5 | Neo-adjuvant (N) | 2019-11-17 | 2019-12-20 | Oxaliplatin + Modified de Gramont | 02 | N | FLUDARABINE + MELPHALAN | 100811977 |
| 10451574 | 10042045 | 1.6 | 0 | Curative (C) | 2019-04-23 | 2019-04-24 | Doxorubicin chemoembolisation | N | N | OSIMERTINIB | 101833820 |
| 10451624 | 10042046 | 1.62 | 95 | Palliative (P) | 2019-12-19 | 2019-12-19 | CHLVPP | 02 | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100630641 |
| 10451638 | 10042047 | 1.76 | 76.7 | Palliative (P) | 2019-05-16 | 2019-05-17 | PARTNER Trial | 02 | N | ATEZOLIZUMAB | 100992115 |
| 10451760 | 10042050 | 1.75 | 50.1 | Curative (C) | 2017-10-02 | 2017-10-13 | CARBOPLATIN + GEMCITABINE | 02 | N | EOX | 100654333 |
| 10451774 | 10042051 | 1.66 | 87 | Curative (C) | 2018-02-16 | 2018-02-26 | AFATINIB | 01 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 101165701 |
| 10451796 | 10042052 | 1.75 | 58.6 | 03 | 2019-10-14 | 2019-11-08 | Obinutuzumab + Venetoclax | 02 | N | MATRIX LYMPHOMA TRIAL | 100355081 |
| 10451887 | 10042053 | 1.73 | 62.4 | Palliative (P) | null | 2019-03-09 | null | N | N | CISPLATIN + PEMETREXED | 101052726 |
| 10451938 | 10042054 | 1.84 | 49.4 | Palliative (P) | null | 2019-08-09 | BEP 5 Day | N | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100580358 |
| 10452003 | 10042058 | 0 | null | Palliative (P) | 2019-03-18 | 2019-03-27 | STAMPEDE TRIAL | 02 | N | IPILIMUMAB | 100185298 |
| 10452090 | 10042059 | 1.84 | 80 | Curative (C) | 2019-07-05 | 2019-07-06 | null | 02 | Y | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101530765 |
| 10452468 | 10042062 | 1.56 | 78 | 03 | 2018-09-06 | 2018-09-06 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 02 | N | REGORAFENIB | 100730289 |
| 10452501 | 10042063 | 1.73 | 51 | Palliative (P) | 2018-02-11 | 2018-02-17 | Nilotinib | 02 | N | CISPLATIN + IFOSFAMIDE + PACLITAXEL | 100847502 |
| 10452517 | 10042064 | 1.54 | 82 | 03 | 2020-02-09 | 2020-02-22 | ECX | 02 | N | TRASTUZUMAB | 101749327 |
| 10452549 | 10042065 | 1.73 | 68.15 | Palliative (P) | 2016-08-30 | 2016-08-30 | CAPECITABINE + PACLITAXEL | 02 | N | CISPLATIN + ETOPOSIDE | 100525208 |
| 10452656 | 10042066 | 0 | 73.9 | Adjuvant (A) | 2018-05-30 | 2018-05-30 | Pentostatin | 2 | N | CARBOPLATIN + FLUOROURACIL | 100476826 |
| 10452817 | 10042067 | 1.42 | 80 | 03 | 2019-04-06 | 2019-04-11 | Cape+Cetuximab+Oxalip (2 wk) Load | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100340906 |
| 10453451 | 10042073 | 1.75 | 74.7 | null | 2019-02-27 | 2019-02-27 | Irinotecan + Modified De Gramont | 02 | null | TIVOZANIB | 100267615 |
| 10453518 | 10042074 | 1.72 | 61.55 | Neo-adjuvant (N) | 2018-10-07 | 2018-10-25 | BLEOMYCIN | 02 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101384957 |
| 10453585 | 10042075 | 1.46 | 76.3 | Neo-adjuvant (N) | 2018-06-15 | 2018-08-16 | VEPEMB | 02 | N | CAPECITABINE + MITOMYCIN + RT | 101386551 |
| 10453660 | 10042076 | 1.52 | 68.9 | 03 | 2016-12-13 | 2021-07-07 | Carboplatin + Docetaxel | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN | 101746091 |
| 10454080 | 10042078 | 1.71 | 105 | Palliative (P) | 2018-01-06 | 2018-01-27 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | Y | EOX | 100556164 |
| 10454119 | 10042079 | 1.72 | 66.5 | null | 2019-07-04 | 2019-07-31 | Letrozole + Palbociclib | 02 | null | IPILIMUMAB | 100185006 |
| 10454222 | 10042080 | 1.57 | 67.3 | Curative (C) | 2016-12-13 | 2016-12-20 | Oxaliplatin + Modified de Gramont | 02 | N | ABEMACICLIB + FULVESTRANT | 100551131 |
| 10454229 | 10042081 | null | 54.8 | Curative (C) | 2017-05-15 | 2017-05-15 | Arsenic Triox + Tretinoin Ind W1-4 | 02 | N | CISPLATIN + DOXORUBICIN + ETOPOSIDE | 101420082 |
| 10454471 | 10042083 | 1.67 | 129 | 03 | 2016-11-06 | 2016-11-08 | Bortezomib + Cyclophos + Dex | 02 | N | FEC | 101669418 |
| 10454508 | 10042084 | 1.64 | 75.8 | null | 2019-09-14 | 2019-10-03 | Apalutamide | Y | Y | FLUOROURACIL + MITOMYCIN + RT | 100364572 |
| 10454560 | 10042085 | null | 70.4 | Neo-adjuvant (N) | 2018-08-16 | 2018-08-16 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | IDELALISIB + RITUXIMAB | 100104553 |
| 10454575 | 10042087 | 0 | 99.2 | null | 2017-08-23 | 2017-09-06 | CAPECITABINE + CARBOPLATIN | 02 | null | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 101407185 |
| 10454607 | 10042088 | 1.89 | null | Palliative (P) | 2021-09-10 | 2021-09-10 | Ixazomib + Lenalidomide | 02 | null | AVELUMAB + AXITINIB | 100873998 |
| 10454613 | 10042089 | 1.64 | 96.9 | 03 | 2017-12-07 | 2017-12-07 | AML 19 TRIAL | null | Y | IDELALISIB + RITUXIMAB | 100396501 |
| 10454721 | 10042090 | 1.58 | 74.5 | 03 | 2021-07-16 | 2021-07-30 | Doxorubicin 75mg/m2 | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101295477 |
| 10454792 | 10042091 | 1.8 | 107 | Palliative (P) | 2018-07-10 | 2018-07-10 | MELPHALAN | 02 | N | CYCLOPHOSPHAMIDE | 101314395 |
| 10454831 | 10042093 | 1.71 | 69.8 | 03 | 2020-05-28 | 2020-06-28 | null | N | N | CISPLATIN + ETOPOSIDE | 100227161 |
| 10454916 | 10042095 | null | null | Curative (C) | 2019-07-01 | 2019-07-03 | AVELUMAB + AXITINIB | 02 | y | RIALTO TRIAL | 101332640 |
| 10454921 | 10042096 | 1.38 | 0 | Curative (C) | null | 2021-09-15 | GemCarbo Days 1+8 | 01 | N | ENRICH TRIAL | 100612267 |
| 10455029 | 10042098 | 1.66 | 73.7 | Adjuvant (A) | null | 2021-05-03 | Brentuximab Vedotin | N | null | CAPECITABINE + CARBOPLATIN | 101250468 |
| 10455133 | 10042100 | 1.8 | 64.2 | Palliative (P) | 2017-04-01 | 2017-04-09 | Fulvestrant + Palbociclib | 02 | N | BLEOMYCIN | 100702548 |
| 10455136 | 10042101 | 1.58 | 73.5 | Palliative (P) | null | 2019-03-18 | AFATINIB | 99 | N | DABRAFENIB | 100981020 |
| 10455223 | 10042102 | 0 | 95.8 | Palliative (P) | 2019-09-22 | 2019-09-22 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 02 | N | FULVESTRANT + PALBOCICLIB | 100792259 |
| 10455288 | 10042103 | 1.54 | null | Curative (C) | null | 2017-01-17 | Cisplatin + Pemetrexed | 01 | N | AML17 TRIAL | 100697064 |
| 10455322 | 10042104 | 1.53 | 60 | Palliative (P) | 2018-01-14 | 2018-02-05 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 02 | N | EVEROLIMUS | 100027122 |
| 10455346 | 10042105 | 1.7 | 91.65 | 03 | 2018-12-07 | 2018-12-27 | Cisplatin + Docetaxel +Fluorouracil | 02 | null | DOXORUBICIN EMBOLISATION | 101620200 |
| 10455455 | 10042106 | 1.63 | 100.65 | null | 2021-05-05 | 2021-05-31 | Paclitaxel+Trastuzumab wkly Maint | 02 | null | OXALIPLATIN + MDG | 100861897 |
| 10455474 | 10042107 | 1.61 | 87.8 | Curative (C) | 2018-05-25 | 2018-05-28 | Cisplatin 100 + RT(H&N) 1 day | 02 | N | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 101712799 |